DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ipragliflozin
Ipragliflozin
Dapagliflozin – Structure, Synthesis, and New Indications
Supplementary Material
International Journal of Pharmacy & Life Sciences
Comparison of Tofogliflozin 20 Mg and Ipragliflozin 50 Mg Used Together
202293Orig1s000
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing
Objectives Anti-Hyperglycemic Therapeutics
Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment
Early Combination Therapy of Empagliflozin and Linagliptin Exerts
Efficacy and Safety of Dapagliflozin in the Elderly
Discovery Awaits You at the 81ST Scientific Sessions
SGLT2 Inhibitors
Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice
Metabolic Control
SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus
Susceptibility to Serious Skin and Subcutaneous Tissue Disorders And
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Top View
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
Adverse Effects and Safety of SGLT2 Inhibitor Use Among Patients with Type 2 Diabetes: Findings from RCT Evidence
Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products
The Kidney As a Treatment Target for Type 2 Diabetes Betsy Dokken, NP, Phd, CDE
Diabetes Dispatch Gestational Diabetes How Do We Recognize and Treat It?
DIABETOLOGY SGLT2 Inhibitors: a Novel Therapy for Type 2 Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: a Meta-Analysis of Randomized Controlled Trials
Clinical Therapeutics/New Technology— Glucose Monitoring and Sensing 2348‑Pub
SGLT2 Inhibitors and Its Role in Diabetes
Drug Interactions of Sglt2 Inhibitors (Gliflozins) Involving Ugt Enzymes Dr
Empagliflozin Reverses Obesity and Insulin Resistance Through Fat Browning and Alternative Macrophage Activation in Mice Fed a High-Fat Diet
Risks Vs Benefits for SGLT2 Inhibitor Medications
The Sodium/Glucose Co-Transporter Inhibitors Are a Growing Repository
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor
Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Canagliflozin As an Initial Therapy in Drug-Naïve
3/23/2015 1 Medications Update – New and Emerging Therapies
(12) Patent Application Publication (10) Pub. No.: US 2013/0137646 A1 WENRICH Et Al
A Focus on Diabetic Ketoacidosis Ashley M
A Literature Review and Meta-Analysis of Safety Profiles of SGLT2 Inhibitors
Empagliflozin (An SGLT2 Inhibitor)
SUJANU® Combination Tablets Combining Type-2 Diabetes Drugs
Efficacy and Safety of Ipragliflozin and Metformin for Visceral Fat Reduction
Modern Management of Diabetes Mellitus Case 1 Case 2 Case 3
Press Release
The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT
Use of Insulin Glargine 100 U/Ml for the Treatment of Type 2 Diabetes Mellitus in East Asians: a Review
Clinical Effectiveness of a Combination of Metformin and Ipragliflozin in the Management of Patients with Type-2 Diabetes Mellitus
Efficacy and Safety of Ipragliflozin As Add-On Therapy to Insulin In
Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults with Overweight Or Obesity: a Systematic Review and Meta-Analysis
Emerging Therapies in Endocrinology and Diabetes
SGLT2 Inhibitors Provide an Effective Therapeutic Option for Diabetes Complicated with Insulin Antibodies
Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients with Type 2 Diabetes: an Open-Label Study
SGLT-2 Receptor Inhibitors for Treating Patients with Type 2 Diabetes
Efficacy and Safety of Ipragliflozin As Add-On Therapy To
Online-Only Supplemental Material
A Complete Review of Empagliflozin
12-Cem-Diabetes-Hand
Effects of SGLT-2 Inhibitors on Mortality and Cardiovascular Events: a Comprehensive Meta-Analysis of Randomized Controlled Trials
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes In
Possibility of Pharmacokinetic Drug Interaction Between a DPP-4 Inhibitor and a SGLT2 Inhibitor
Type 2 Diabetes Mellitus 2014